COCHW · Envoy Medical, Inc.

Envoy Medical's first quarter 2026 results reflect a transformative period centered on clinical and financial milestones. Revenue remained nominal at $39,000, as the company is pre-commercialization. R&D expenses rose 32.5% to $3.6 million, driven by increased clinical trial activity and personnel costs during enrollment. Sales and marketing expenses declined 54.2% to $164,000 due to resource reallocation to R&D. General and administrative expenses increased modestly to $1.9 million. The company ended the quarter with $25.3 million in cash, a significant improvement from $3.7 million at year-end 2025, following the closing of an upsized public offering for up to $78 million. The pivotal trial enrollment of 56 patients for the Acclaim cochlear implant was completed on March 11, 2026, a first for a fully implanted cochlear implant seeking FDA approval. Interim six-month data from the first 10 patients showed no serious adverse events, mean CNC word recognition improvement from 15.2% to 39.2%, and median daily wear time of 24 hours. The first three patients reached the 12-month endpoint, keeping the company on track for PMA submission. Management expressed confidence in advancing toward commercialization, supported by a strengthened balance sheet and expanded IP portfolio. The appointment of Chas McKhann to the board adds medical device expertise as the company prepares for commercial launch.